Model protocol to study pharmacogenomics in inflammatory diseases: Human rheumatoid arthritis

Mukundan Attur, Clifton O. Bingham, Mandar Dave, Steven B. Abramson, Ashok R. Amin

Research output: Contribution to journalArticle

Abstract

Pharmacogenomics is a revolution in molecular medicine, especially in view of the development of microarray technologies and proteomics to monitor gene and protein expression. The ability to monitor up to 60,000 potential parameters in a clinical setting gives a whole new meaning to 1) toxic effects, 2) side effects, 3) primary and secondary targets, and 4) drug resistance and nonresponders during a clinical trial. Pharmacogenomics may set a new standard to monitor the effects of drugs such as NSAIDS or disease- modifying drugs in diseases such as arthritis. The present article outlines a pharmacogenomics clinical protocol that is in progress, a study that will address some of the above questions. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)29-33
Number of pages5
JournalDrug Development Research
Volume49
Issue number1
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

    Fingerprint

Keywords

  • Clinical trials
  • DMARD
  • Genomics
  • NSAIDs
  • Pharmacogenomics
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Drug Discovery

Cite this